Kyntra Bio Inc

Financials

Activos totales 214.53 M165.21 M178.06 M137.01 M119.59 M Total de pasivos 398.16 M340.14 M359.08 M119.53 M115.12 M Capital total -205.12 M-196.41 M-202.51 M-4 M-17 M Total de pasivos y patrimonio neto 214.53 M165.21 M178.06 M137.01 M119.59 M Deuda total 73.13 M73.42 M73.73 M00 Deuda neta 22.64 M39.81 M50.37 M-117.97 M-88.98 M

Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate. On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB.